Drug intelligence / Profile preview

vancomycin + gentamicin

Development stage: Preclinical
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Intravenous

Overview

A combination antibiotic therapy consisting of vancomycin (a glycopeptide antibiotic) and gentamicin (an aminoglycoside antibiotic). This combination demonstrates synergistic activity against various bacterial pathogens, particularly methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant pneumococci, and enterococci. The synergistic mechanism appears to be based on vancomycin's ability to increase cell wall permeability, allowing enhanced intracellular penetration of gentamicin.

Brand names: Garamycin + VancocinGaramycin + Firvanq
Other names: gentamicin + vancomycingentamicin sulfate + vancomycin hydrochloride

Targets

D-Ala-D-Ala (D-Ala-D-Ala terminus)30S A-site (Bacterial ribosomal 30S A-site)

Beyond the preview

Go deeper on vancomycin + gentamicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vancomycin + gentamicin.

Explore the full profile